0001209191-22-030549.txt : 20220519
0001209191-22-030549.hdr.sgml : 20220519
20220519165035
ACCESSION NUMBER: 0001209191-22-030549
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220519
FILED AS OF DATE: 20220519
DATE AS OF CHANGE: 20220519
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Muralidhar Bali
CENTRAL INDEX KEY: 0001784138
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39011
FILM NUMBER: 22943809
MAIL ADDRESS:
STREET 1: C/O EXICURE, INC.
STREET 2: 8045 LAMON AVENUE, SUITE 410
CITY: SKOKIE
STATE: IL
ZIP: 60077
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXICURE, INC.
CENTRAL INDEX KEY: 0001698530
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 815333008
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2430 N. HALSTED ST.
CITY: CHICAGO
STATE: IL
ZIP: 60614
BUSINESS PHONE: 847-673-1700
MAIL ADDRESS:
STREET 1: 2430 N. HALSTED ST.
CITY: CHICAGO
STATE: IL
ZIP: 60614
FORMER COMPANY:
FORMER CONFORMED NAME: Max-1 Acquisition Corp
DATE OF NAME CHANGE: 20170221
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-19
0
0001698530
EXICURE, INC.
XCUR
0001784138
Muralidhar Bali
C/O EXICURE, INC.
2430 N. HALSTED STREET
CHICAGO
IL
60614
1
0
0
0
Common Stock
2022-05-19
4
P
0
1472126
0.1937
A
8449126
I
See footnotes
The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, (together with Abingworth Bioventures VII GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures VII GP LP. Abingworth VII (acting by its general partner Abingworth Bioventures VII GP LP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth VII. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth VII.
Each of Abingworth VII, Abingworth LLP, the General Partners, the Reporting Person and each member of the investment committee disclaims beneficial ownership of the common stock held by Abingworth VII, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ John Heard, Attorney-in-Fact
2022-05-19